Trial Profile
A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Peginterferon alfa-2a (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms ACTIVATE
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 13 Mar 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2023.
- 06 Jul 2022 Planned End Date changed from 1 Dec 2021 to 1 Jan 2023.